MILPITAS, Calif. – October 17, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President, Global Marketing. Alex possesses more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide.
Most recently, Alex served as Divisional Vice President of Global Marketing for Abbott Vascular, where he was responsible for the long-term strategy and marketing of the division’s coronary, endovascular, imaging and physiology portfolios. Prior to that, Alex led the global marketing function for Abbott Structural Heart and its portfolio of transcatheter valve and congenital heart disease technologies, with a major focus on market development. He has also held roles of increasing responsibility at Medtronic, where he contributed to the development and launch of multiple generations of drug-eluting stents and other vascular technologies. Alex holds a bachelor’s degree in marketing from Western Michigan University and an MBA from Thunderbird School of Global Management at Arizona State University.
“Alex’s global leadership in developing and establishing diverse therapies across important market segments will be critical as Elixir expands its broad portfolio of innovative products in interventional cardiology and peripheral vascular markets,” said Elixir Medical President and Chief Operating Officer Vinayak Bhat, PhD.
“Elixir’s disruptive innovation will enable extraordinary clinical therapies to be available to clinicians for their patients globally,” said Mr. Nepogodiev. “I am honored to join such a dynamic organization, and excited about becoming a part of the excellent leadership team.”
ABOUT ELIXIR MEDICAL
Elixir Medical Corporation, a privately-funded company based in Milpitas, California, develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company’s mission is to transform the care of patients with heart and vascular disease through innovation.